Now showing items 342-361 of 3706

    • BRD4 facilitates replication stress-induced DNA damage response. 

      Zhang, J; Dulak, AM; Hattersley, MM; Willis, BS; Nikkilä, J; Wang, A; Lau, A; Reimer, C; Zinda, M; Fawell, SE; Mills, GB; Chen, H (2018-07)
      Previous reports have demonstrated that select cancers depend on BRD4 to regulate oncogenic gene transcriptional programs. Here we describe a novel role for BRD4 in DNA damage response (DDR). BRD4 associates with and ...
    • BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. 

      Li, X; Baek, G; Ramanand, SG; Sharp, A; Gao, Y; Yuan, W; Welti, J; Rodrigues, DN; Dolling, D; Figueiredo, I; Sumanasuriya, S; Crespo, M; Aslam, A; Li, R; Yin, Y; Mukherjee, B; Kanchwala, M; Hughes, AM; Halsey, WS; Chiang, C-M; Xing, C; Raj, GV; Burma, S; de Bono, J; Mani, RS (2018-01)
      BRD4 belongs to the bromodomain and extraterminal (BET) family of chromatin reader proteins that bind acetylated histones and regulate gene expression. Pharmacological inhibition of BRD4 by BET inhibitors (BETi) has indicated ...
    • Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif 

      Bradshaw, PS; Condie, A; Matutes, E; Catovsky, D; Yuille, MR (2002-01-17)
      The mature sporadic T-cell malignancy, T-cell prolymphocytic leukemia (T-PLL) is remarkable for frequently harbouring somatic mutations of the Ataxia Telangiectasia (A-T) gene, ATM. Because some data suggest ATM is frequently ...
    • Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients. 

      Dodson, A; Parry, S; Ibrahim, M; Bartlett, JM; Pinder, S; Dowsett, M; Miller, K (2018-10)
      We describe a collated data set of results from clinical testing of breast cancers carried out between 2009 and 2016 in the United Kingdom and Republic of Ireland. More than 199 000 patient biomarker data sets, together ...
    • Breast cancer intratumor genetic heterogeneity: causes and implications 

      Ng, CKY; Pemberton, HN; Reis-Filho, JS (EXPERT REVIEWS, 2012-08)
      There is burgeoning evidence to suggest that tumor evolution follows the laws of Darwinian evolution, whereby individual tumor cell clones harbor private genetic aberrations in addition to the founder mutations, and that ...
    • Breast cancer onset in twins and women with bilateral disease 

      Hartman, M; Hall, P; Edgren, G; Reilly, M; Lindstrom, L; Lichtenstein, P; Kaprio, J; Skytthe, A; Peto, J; Czene, K (AMER SOC CLINICAL ONCOLOGY, 2008-09-01)
      Purpose Little is known of the onset of breast cancer in high- risk populations. We investigated the risk of breast cancer in twin sisters and in the contralateral breast taking family history into consideration. Patients ...
    • Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. 

      Nichols, HB; Schoemaker, MJ; Cai, J; Xu, J; Wright, LB; Brook, MN; Jones, ME; Adami, H-O; Baglietto, L; Bertrand, KA; Blot, WJ; Boutron-Ruault, M-C; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Hoffman-Bolton, J; Kaaks, R; Key, TJ; Kitahara, CM; Larsson, SC; Linet, M; Merritt, MA; Milne, RL; Pala, V; Palmer, JR; Peeters, PH; Riboli, E; Sund, M; Tamimi, RM; Tjønneland, A; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Wolk, A; Zheng, W; Weinberg, CR; Swerdlow, AJ; Sandler, DP (2019-01)
      Background:Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or ...
    • Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. 

      Cooke, R; Jones, ME; Cunningham, D; Falk, SJ; Gilson, D; Hancock, BW; Harris, SJ; Horwich, A; Hoskin, PJ; Illidge, T; Linch, DC; Lister, TA; Lucraft, HH; Radford, JA; Stevens, AM; Syndikus, I; Williams, MV; England and Wales Hodgkin Lymphoma Follow-up Group; Swerdlow, AJ (2013-06)
      BACKGROUND: Women treated with supradiaphragmatic radiotherapy (sRT) for Hodgkin lymphoma (HL) at young ages have a substantially increased breast cancer risk. Little is known about how menarcheal and reproductive factors ...
    • Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study. 

      Wright, LB; Schoemaker, MJ; Jones, ME; Ashworth, A; Swerdlow, AJ (2018-03-08)
      Preeclampsia and hyperemesis are pregnancy complications associated with altered sex hormone levels. Previous studies suggest preeclampsia may be associated with a decreased risk of subsequent breast cancer and hyperemesis ...
    • Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study. 

      Wright, LB; Schoemaker, MJ; Jones, ME; Ashworth, A; Swerdlow, AJ (2018-08)
      Preeclampsia and hyperemesis gravidarum are pregnancy complications associated with altered sex hormone levels. Previous studies suggest preeclampsia may be associated with a decreased risk of subsequent breast cancer and ...
    • Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. 

      Clendenen, TV; Ge, W; Koenig, KL; Afanasyeva, Y; Agnoli, C; Brinton, LA; Darvishian, F; Dorgan, JF; Eliassen, AH; Falk, RT; Hallmans, G; Hankinson, SE; Hoffman-Bolton, J; Key, TJ; Krogh, V; Nichols, HB; Sandler, DP; Schoemaker, MJ; Sluss, PM; Sund, M; Swerdlow, AJ; Visvanathan, K; Zeleniuch-Jacquotte, A; Liu, M (2019-03-19)
      BACKGROUND:Models that accurately predict risk of breast cancer are needed to help younger women make decisions about when to begin screening. Premenopausal concentrations of circulating anti-Müllerian hormone (AMH), a ...
    • Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. 

      Dunning, AM; Michailidou, K; Kuchenbaecker, KB; Thompson, D; French, JD; Beesley, J; Healey, CS; Kar, S; Pooley, KA; Lopez-Knowles, E; Dicks, E; Barrowdale, D; Sinnott-Armstrong, NA; Sallari, RC; Hillman, KM; Kaufmann, S; Sivakumaran, H; Moradi Marjaneh, M; Lee, JS; Hills, M; Jarosz, M; Drury, S; Canisius, S; Bolla, MK; Dennis, J; Wang, Q; Hopper, JL; Southey, MC; Broeks, A; Schmidt, MK; Lophatananon, A; Muir, K; Beckmann, MW; Fasching, PA; Dos-Santos-Silva, I; Peto, J; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Flyger, H; González-Neira, A; Perez, JIA; Anton-Culver, H; Eunjung, L; Arndt, V; Brenner, H; Meindl, A; Schmutzler, RK; Brauch, H; Hamann, U; Aittomäki, K; Blomqvist, C; Ito, H; Matsuo, K; Bogdanova, N; Dörk, T; Lindblom, A; Margolin, S; Kosma, V-M; Mannermaa, A; Tseng, C-C; Wu, AH; Lambrechts, D; Wildiers, H; Chang-Claude, J; Rudolph, A; Peterlongo, P; Radice, P; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Henderson, BE; Goldberg, MS; Teo, SH; Yip, CH; Nord, S; Borresen-Dale, A-L; Kristensen, V; Long, J; Zheng, W; Pylkäs, K; Winqvist, R; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; Figueroa, J; Sherman, ME; Czene, K; Darabi, H; Hollestelle, A; van den Ouweland, AMW; Humphreys, K; Gao, Y-T; Shu, X-O; Cox, A; Cross, SS; Blot, W; Cai, Q; Ghoussaini, M; Perkins, BJ; Shah, M; Choi, J-Y; Kang, D; Lee, SC; Hartman, M; Kabisch, M; Torres, D; Jakubowska, A; Lubinski, J; Brennan, P; Sangrajrang, S; Ambrosone, CB; Toland, AE; Shen, C-Y; Wu, P-E; Orr, N; Swerdlow, A; McGuffog, L; Healey, S; Lee, A; Kapuscinski, M; John, EM; Terry, MB; Daly, MB; Goldgar, DE; Buys, SS; Janavicius, R; Tihomirova, L; Tung, N; Dorfling, CM; van Rensburg, EJ; Neuhausen, SL; Ejlertsen, B; Hansen, TVO; Osorio, A; Benitez, J; Rando, R; Weitzel, JN; Bonanni, B; Peissel, B; Manoukian, S; Papi, L; Ottini, L; Konstantopoulou, I; Apostolou, P; Garber, J; Rashid, MU; Frost, D; EMBRACE; Izatt, L; Ellis, S; Godwin, AK; Arnold, N; Niederacher, D; Rhiem, K; Bogdanova-Markov, N; Sagne, C; Stoppa-Lyonnet, D; Damiola, F; GEMO Study Collaborators; Sinilnikova, OM; Mazoyer, S; Isaacs, C; Claes, KBM; De Leeneer, K; de la Hoya, M; Caldes, T; Nevanlinna, H; Khan, S; Mensenkamp, AR; HEBON; Hooning, MJ; Rookus, MA; Kwong, A; Olah, E; Diez, O; Brunet, J; Pujana, MA; Gronwald, J; Huzarski, T; Barkardottir, RB; Laframboise, R; Soucy, P; Montagna, M; Agata, S; Teixeira, MR; kConFab Investigators; Park, SK; Lindor, N; Couch, FJ; Tischkowitz, M; Foretova, L; Vijai, J; Offit, K; Singer, CF; Rappaport, C; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Imyanitov, EN; Hulick, PJ; Phillips, K-A; Piedmonte, M; Mulligan, AM; Glendon, G; Bojesen, A; Thomassen, M; Caligo, MA; Yoon, S-Y; Friedman, E; Laitman, Y; Borg, A; von Wachenfeldt, A; Ehrencrona, H; Rantala, J; Olopade, OI; Ganz, PA; Nussbaum, RL; Gayther, SA; Nathanson, KL; Domchek, SM; Arun, BK; Mitchell, G; Karlan, BY; Lester, J; Maskarinec, G; Woolcott, C; Scott, C; Stone, J; Apicella, C; Tamimi, R; Luben, R; Khaw, K-T; Helland, Å; Haakensen, V; Dowsett, M; Pharoah, PDP; Simard, J; Hall, P; García-Closas, M; Vachon, C; Chenevix-Trench, G; Antoniou, AC; Easton, DF; Edwards, SL (2016-04)
      We analyzed 3,872 common genetic variants across the ESR1 locus (encoding estrogen receptor α) in 118,816 subjects from three international consortia. We found evidence for at least five independent causal variants, each ...
    • Breast cancer survivorship: key issues and priorities of care 

      Iyer, R; Ring, A (Royal College of General Practitioners, 2017-03)
    • Breast cancer susceptibility - A new look at an old model 

      Peto, J (2002-06)
      A polygenic model in which many individually weak genes combine multiplicately to cause a 50-fold range of risk in the population explains several puzzling aspects of familial breast cancer epidemiology, including the very ...
    • Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent. 

      Johnson, L; O'Donoghue, JM; McLean, N; Turton, P; Khan, AA; Turner, SD; Lennard, A; Collis, N; Butterworth, M; Gui, G; Bristol, J; Hurren, J; Smith, S; Grover, K; Spyrou, G; Krupa, K; Azmy, IA; Young, IE; Staiano, JJ; Khalil, H; MacNeill, FA (2017-08)
      Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare, Non-Hodgkin lymphoma arising in the capsule of breast implants. BIA-ALCL presents as a recurrent effusion and/or mass. Tumours exhibit CD30 ...
    • Breast MRI segmentation for density estimation: Do different methods give the same results and how much do differences matter? 

      Doran, SJ; Hipwell, JH; Denholm, R; Eiben, B; Busana, M; Hawkes, DJ; Leach, MO; Silva, IDS (2017-09)
      PURPOSE:To compare two methods of automatic breast segmentation with each other and with manual segmentation in a large subject cohort. To discuss the factors involved in selecting the most appropriate algorithm for automatic ...
    • Breast reconstruction and post-mastectomy radiation practice 

      Chen, SA; Hiley, C; Nickleach, D; Petsuksiri, J; Andic, F; Riesterer, O; Switchenko, JM; Torres, MA (BIOMED CENTRAL LTD, 2013-03-02)
      Purpose: The goal of this study was to explore the perspectives and practice of radiation oncologists who treat breast cancer patients who have had breast reconstruction. Methods: In 2010, an original electronic survey was ...
    • Bridging the age gap in breast cancer: evaluation of decision support interventions for older women with operable breast cancer: protocol for a cluster randomised controlled trial. 

      Collins, K; Reed, M; Lifford, K; Burton, M; Edwards, A; Ring, A; Brain, K; Harder, H; Robinson, T; Cheung, KL; Morgan, J; Audisio, R; Ward, S; Richards, P; Martin, C; Chater, T; Pemberton, K; Nettleship, A; Murray, C; Walters, S; Bortolami, O; Armitage, F; Leonard, R; Gath, J; Revell, D; Green, T; Wyld, L (2017-07-31)
      INTRODUCTION:While breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes among the older age group. It is inevitable ...
    • Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. 

      Camidge, DR; Kim, HR; Ahn, M-J; Yang, JC-H; Han, J-Y; Lee, J-S; Hochmair, MJ; Li, JY-C; Chang, G-C; Lee, KH; Gridelli, C; Delmonte, A; Garcia Campelo, R; Kim, D-W; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Califano, R; Ghosh, S; Spira, A; Gettinger, SN; Tiseo, M; Gupta, N; Haney, J; Kerstein, D; Popat, S (2018-11)
      BACKGROUND:Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of ...
    • Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant 

      Hiwarkar, P; Amrolia, P; Sivaprakasam, P; Lum, SH; Doss, H; O’Rafferty, C; Petterson, T; Patrick, K; Silva, J; Slatter, M; Lawson, S; Rao, K; Steward, C; Gassas, A; Veys, P; Wynn, R (American Society of Hematology, 2017-04-06)
      <jats:title>Key Points</jats:title> <jats:p>Brincidofovir has superior antiadenoviral activity and safety profile compared with cidofovir. Brincidofovir is highly efficacious in controlling adenoviremia during the lymphopenic ...